[Efficacy and safety of huperzine A in treating patients with mild cognitive impairment: a systematic review and Meta-analysis]

Zhongguo Zhong Yao Za Zhi. 2019 Feb;44(3):582-588. doi: 10.19540/j.cnki.cjcmm.20180925.008.
[Article in Chinese]


To evaluate the efficacy and safety of huperzine in treating patients with mild cognitive impairment. The randomized controlled trials(RCT) were retrieved from EMbase, Cochrane Library, PubMed, CNKI, Wanfang and VIP. The methodology quality of the included studies was evaluated, and a Meta-analysis was performed using RevMan 5.3 software. A total of nine RCTs were included. The Meta-analysis results showed that compared with placebo, Huperzine significantly increased the scores of memory quotient(MQ) and mini-mental state examination(MMSE). However, there was no statistical difference between oral tablet and capsule. Compared with placebo, huperzine A was superior in the scores of MQ and MMSE. Huperzine is safe with mild side effects. Due to the low quality of original studies, more high-quality studies are needed to verify its efficacy.

Keywords: benign memory disorders; efficacy; huperzine A; mild cognitive impairment; safety; systematic review.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Alkaloids / therapeutic use*
  • Cognitive Dysfunction / drug therapy*
  • Humans
  • Memory
  • Randomized Controlled Trials as Topic
  • Sesquiterpenes / therapeutic use*


  • Alkaloids
  • Sesquiterpenes
  • huperzine A